BioCentury | Oct 4, 2019
Company News
Icosavax’s self-assembling vaccine platform
Icosavax believes its computationally designed virus-like particles will open the clinically validated vaccine modality to a broader range of infectious diseases. The company expects its $51 million series A round, announced Thursday, to carry its...